Pharmacokinetics of Exosomes—An Important Factor for Elucidating the Biological Roles of Exosomes and for the Development of Exosome-Based Therapeutics

Journal of Pharmaceutical Sciences

Volumn 106, Issue 9, 2017, Pages 2265-2269

  Morishita, Masaki ^a   Takahashi, Yuki ^a   Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

biological functions; exosomes; pharmacokinetics; therapeutics

Indexed keywords

ALPHA6BETA4 INTEGRIN; ALPHAVBETA5 INTEGRIN; PHOSPHATIDYLSERINE; DRUG;

BIOACCUMULATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; CLEARANCE; ENDOTHELIAL PERMEABILITY; EXOSOME; HALF LIFE TIME; HUMAN; MACROPHAGE; METASTASIS; MOLECULAR THERAPY; NONHUMAN; PERMEABILITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; TISSUE DISTRIBUTION; ANIMAL; DRUG DELIVERY SYSTEM; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALS; DRUG DELIVERY SYSTEMS; EXOSOMES; HUMANS; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 85017473060     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2017.02.030     Document Type: Short Survey

References (46)

1. Théry, C., Ostrowski, M., Segura, E., Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9 (2009), 581–593.
2. Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., Lötvall, J.O., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9 (2007), 654–659.
3. Tominaga, N., Kosaka, N., Ono, M., et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier. Nat Commun, 6, 2015, 6716.
4. Skog, J., Würdinger, T., van Rijn, S., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10 (2008), 1470–1476.
5. Miller, I.V., Grunewald, T.G., Tumour-derived exosomes: tiny envelopes for big stories. Biol Cell 107 (2015), 287–305.
6. Bruno, S., Grange, C., Deregibus, M.C., et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 20 (2009), 1053–1067.
7. Lai, R.C., Arslan, F., Lee, M.M., et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 4 (2010), 214–222.
8. Xin, H., Li, Y., Buller, B., et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells 30 (2012), 1556–1564.
9. Lee, C., Mitsialis, S.A., Aslam, M., et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 126 (2012), 2601–2611.
10. Lener, T., Gimona, M., Aigner, L., et al. Applying extracellular vesicles based therapeutics in clinical trials—an ISEV position paper. J Extracell Vesicles, 4, 2015, 30087.
11. Wolfers, J., Lozier, A., Raposo, G., et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7 (2001), 297–303.
12. Morishita, M., Takahashi, Y., Matsumoto, A., Nishikawa, M., Takakura, Y., Exosome-based tumor antigens—adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials 111 (2016), 55–65.
13. Dai, S., Wei, D., Wu, Z., et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 16 (2008), 782–790.
14. Zitvogel, L., Regnault, A., Lozier, A., et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes. Nat Med 4 (1998), 594–600.
15. Pitt, J.M., Charrier, M., Viaud, S., et al. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol 193 (2014), 1006–1011.
16. Viaud, S., Thery, C., Ploix, S., et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next?. Cancer Res 70 (2010), 1281–1285.
17. Peinado, H., Alečković, M., Lavotshkin, S., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18 (2012), 883–891.
18. Grange, C., Tapparo, M., Bruno, S., et al. Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a model of acute kidney injury monitored by optical imaging. Int J Mol Med 33 (2014), 1055–1063.
19. Wiklander, O.P., Nordin, J.Z., O'Loughlin, A., et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles, 4, 2015, 26316.
20. Smyth, T., Kullberg, M., Malik, N., Smith-Jones, P., Graner, M.W., Anchordoquy, T.J., Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J Control Release 199 (2015), 145–155.
21. Munagala, R., Aqil, F., Jeyabalan, J., Gupta, R.C., Bovine milk-derived exosomes for drug delivery. Cancer Lett 371 (2016), 48–61.
22. Takahashi, Y., Nishikawa, M., Shinotsuka, H., et al. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J Biotechnol 165 (2013), 77–84.
23. Charoenviriyakul, C., Takahashi, Y., Morishita, M., Matsumoto, A., Nishikawa, M., Takakura, Y., Cell type-specific and common characteristics of exosomes derived from mouse cell lines: yield, physicochemical properties, and pharmacokinetics. Eur J Pharm Sci 96 (2017), 316–322.
24. Lai, C.P., Mardini, O., Ericsson, M., et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 8 (2014), 483–494.
25. Morishita, M., Takahashi, Y., Nishikawa, M., et al. Quantitative analysis of tissue distribution of the B16BL6-derived exosomes using a streptavidin–lactadherin fusion protein and Iodine-125-labeled biotin derivative after intravenous injection in mice. J Pharm Sci 104 (2015), 705–713.
26. Hu, L., Wickline, S.A., Hood, J.L., Magnetic resonance imaging of melanoma exosomes in lymph nodes. Magn Reson Med 74 (2015), 266–271.
27. Kotmakçı, M., Çetintaş, V., Extracellular vesicles as natural nanosized delivery systems for small-molecule drugs and genetic material: steps towards the future nanomedicines. J Pharm Pharm Sci 18 (2015), 396–413.
28. Bruno, S., Grange, C., Collino, F., et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One, 7, 2012, e33115.
29. Gatti, S., Bruno, S., Deregibus, M.C., et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transpl 26 (2011), 1474–1483.
30. Badr, C.E., Tannous, B.A., Bioluminescence imaging: progress and applications. Trends Biotechnol 29 (2011), 624–633.
31. Imai, T., Takahashi, Y., Nishikawa, M., et al. Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice. J Extracell Vesicles, 4, 2015, 26238.
32. Kim, S.H., Bianco, N.R., Shufesky, W.J., Morelli, A.E., Robbins, P.D., Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J Immunol 179 (2007), 2242–2249.
33. Chow, A., Zhou, W., Liu, L., et al. Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-κB. Sci Rep, 4, 2014, 5750.
34. Fadok, V.A., Bratton, D.L., Rose, D.M., Pearson, A., Ezekewitz, R.A.B., Henson, P.M., A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405 (2000), 85–90.
35. Subra, C., Laulagnier, K., Perret, B., Record, M., Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie 89 (2007), 205–212.
36. Matsumoto, A., Takahashi, Y., Nishikawa, M., et al. Role of phosphatidylserine-derived negative surface charges in the recognition and uptake of intravenously injected B16BL6-derived exosomes by macrophages. J Pharm Sci 106 (2017), 168–175.
37. Watson, D.C., Bayik, D., Srivatsan, A., et al. Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials 105 (2016), 195–205.
38. Hao, S., Bai, O., Li, F., Yuan, J., Laferte, S., Xiang, J., Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology 120 (2007), 90–102.
39. Saunderson, S.C., Dunn, A.C., Crocker, P.R., McLellan, A.D., CD169 mediates the capture of exosomes in spleen and lymph node. Blood 123 (2014), 208–216.
40. Hoshino, A., Costa-Silva, B., Shen, T., et al. Tumour exosome integrins determine organotropic metastasis. Nature 527 (2015), 329–335.
41. Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., Wood, M.J., Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29 (2011), 341–345.
42. Cooper, J.M., Wiklander, P., Nordin, J.Z., et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord 29 (2014), 1476–1485.
43. Liu, Y., Li, D., Liu, Z., et al. Targeted exosome-mediated delivery of opioid receptor mu siRNA for the treatment of morphine relapse. Sci Rep, 5, 2015, 17543.
44. Tian, Y., Li, S., Song, J., et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35 (2014), 2383–2390.
45. Ohno, S., Takanashi, M., Sudo, K., et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 21 (2013), 185–191.
46. Kooijmans, S., Fliervoet, L., Van Der Meel, R., et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J Control Release 224 (2016), 77–85.